Xenon Pharmaceuticals closed at $39.19 on Nov 4, up 2.51%, 44.8% below its 52-week closing high. Volume of 1.7M shares was 1.21× its 20-day average (close to normal).
Split-adjusted performance: +7.2% over one month, -33.1% over six months, -4.7% over one year.
Short interest was 7.3M shares at the Oct 15 settlement, up 21.6% from the prior report (8.1% of float, 4.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| XENEXenon Pharmaceuticals | $39.19 | +2.51% | −33.1% | — | — | — | $3.80B | |
| PBLSParabilis Medicines | $30.36 | +3.79% | — | — | −45239.9% | — | $3.75B | Compare |
| ACADAcadia Pharmaceuticals | $21.47 | +4.38% | 0.0% | +16.4% | 10.2% | 9.7 | $3.70B | Compare |
| IRONDisc Medicine | $83.28 | +2.61% | +21.3% | — | — | — | $3.70B | Compare |
| AMLXAmylyx Pharmaceuticals | $29.40 | +0.68% | +83.1% | — | — | — | $3.69B | Compare |
| TNGXTango Therapeutics | $23.18 | +0.04% | −1.9% | −100.0% | — | — | $3.91B | Compare |
| OGNOrganon & | $13.83 | −0.14% | +3.1% | −1.7% | 10.4% | 17.1 | $3.63B | Compare |
| ABCLAbCellera Biologics | $12.28 | +0.82% | +143.7% | −76.3% | −1368.6% | — | $3.98B | Compare |
| VKTXViking Therapeutics | $27.97 | +7.21% | −13.4% | — | — | — | $3.57B | Compare |
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
